Abstract
Alzheimer’s disease is a chronic neurodegenerative disease that accounts for up to 80% of all dementias. Characterised by deteriorations of memory and cognitive function, the key neuropathological features are accumulations of β-amyloid and hyperphosphorylated tau, as ‘plaques’ and ‘tangles’, respectively. Despite extensive study, however, the exact mechanism underlying aggregate formation in Alzheimer’s disease remains elusive, as does the contribution of these aggregates to disease progression. Importantly, a recent evaluation of current Alzheimer’s disease animal models suggested that rodent models are not able to fully recapitulate the pathological intricacies of the disease as it occurs in humans. Therefore, increasing attention is being paid to species that might make good alternatives to rodents for studying the molecular pathology of Alzheimer’s disease. The sheep (Ovis aries) is one such species, although to date, there have been few molecular studies relating to Alzheimer’s disease in sheep. Here, we investigated the Alzheimer’s disease relevant histopathological characteristics of 22 sheep, using anti-β-amyloid (Abcam 12267 and mOC64) and phosphorylation specific anti-tau (AT8 and S396) antibodies. We identified numerous intraneuronal aggregates of both β-amyloid and tau that are consistent with early Alzheimer’s disease-like pathology. We confirmed the expression of two 3-repeat (1N3R, 2N3R) and two 4-repeat (1N4R, 2N4R) tau isoforms in the ovine brain, which result from the alternative splicing of two tau exons. Finally, we investigated the phosphorylation status of the serine396 residue in 30 sheep, and report that the phosphorylation of this residue begins in sheep aged as young as 2 years. Together, these data show that sheep exhibit naturally occurring β-amyloid and tau pathologies, that reflect those that occur in the early stages of Alzheimer’s disease. This is an important step towards the validation of the sheep as a feasible large animal species in which to model Alzheimer’s disease.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that presents with debilitating memory and cognitive impairments, and accounts for between 60 and 80% of all dementias worldwide [100]. Whilst the prevalence and the consequent economic and social impacts of AD are predicted to increase each year as the global population ages, the exact aetiology of AD is still unknown, making the development of effective treatments extremely challenging [20]. Accumulations of β-amyloid (Aβ) exhibited as extracellular plaques and cerebral amyloid angiopathy (CAA), and accumulations of hyperphosphorylated tau present as paired helical filaments (PHFs) and neurofibrillary tangles (NFTs) are accompanied by significant neuronal loss and constitute the primary histopathological hallmarks of the disease [11, 20].
One particular challenge of using rodent species for preclinical studies is that rodents do not naturally exhibit either Aβ or tau pathology as they age [26]. To overcome this obstacle, it has been necessary to create transgenic mouse models overexpressing Aβ [68]. Such models have been used to elucidate the significance of mutations in the amyloid precursor (APP), and presenilin proteins (PSEN1 and PSEN2) that cause familial AD (FAD) [26]. Mutations in these proteins affect APP metabolism, leading to an increased production of the amyloidogenic form of Aβ (Aβ1–42), and impaired Aβ clearance [38]. These events form the basis of the ‘amyloid cascade hypothesis’ to explain the pathogenesis of AD, in which it is proposed that accumulation of Aβ1–42 is the primary pathological event that drives all other associated pathologies (including tau pathology, inflammation, vascular damage, and neuronal loss) [36]. This hypothesis, however, does not explain the mechanisms by which soluble and/or insoluble forms of intracellular and/or extracellular aggregates of Aβ and tau differentially affect one another [50, 75]. Indeed, while transgenic mouse models using APP and PSEN mutations present with significant Aβ pathology between three and six months of age they often fail to exhibit significant tau pathology or neuron loss [26]. Consequently, tau pathologies within these rodent models are achieved only by introducing tau mutations that cause tau pathology in other dementias, namely those associated with frontotemporal dementia with parkinsonism-17 (FTDP-17) [26]. This, combined with the relatively short lifespan of rodents means that the capacity of transgenic mouse models to fully reflect the aetiological mechanisms and temporal progression of familial AD is limited [81]. Furthermore, given the lack of naturally occurring age-related neuropathology, the ability of mouse models to recapitulate mechanisms associated with ‘sporadic’ AD (that is not associated with mutations in any of the FAD genes and accounts for more than 95% of AD cases), is also extremely restricted [22].
Increasing recognition of the limitations associated with rodent models of AD has led to the investigation of species that have a longer lifespan, a more physically and functionally differentiated brain, and a propensity to naturally develop both Aβ and tau pathology with age [23, 80]. Non-human primates such as the chimpanzee (Pan troglodytes), rhesus macaque (Macaca mulatta) and common marmoset (Callithrix jacchus) are of particular interest, because they naturally develop some AD-like pathology [41]. For example, diffuse and dense-cored Aβ plaques, and CAA have been detected in aged chimpanzees [25, 28, 30, 78], rhesus macaques [79, 96] and marmosets [35, 58], with quantities of Aβ in aged individuals comparable to levels seen in AD patients. NFTs have also been described within the entorhinal cortex of aged chimpanzees and rhesus macaques [4], while in marmosets, abnormally phosphorylated tau has been identified as early as adolescence [77]. A range of other species have been found to exhibit spontaneous AD-like pathology. Such species include the gorilla (Gorilla gorilla gorilla [71] and Gorilla beringei beringei [72]), Ursidae species [16, 88, 95], cetacean species [88], and pinniped species [92]. The domestic dog (Canis familiaris) [17, 18, 80, 86] and cat (Felis catus) [12] also develop cognitive decline alongside diffuse Aβ plaques in old age. However, tau pathology rarely accompanies Aβ deposition and dense-cored Aβ plaques and NFTs are not consistently detected. Whilst non-human primates, dogs and cats have the potential to mitigate the limitations of current rodent AD models, they are limited in terms of their ethical use and, therefore, their numbers available to facilitate robust experimental design.
We chose to focus on sheep as a potential animal model of human AD for a number of reasons. Sheep have a moderate lifespan (15–20 years), an extensively annotated reference genome [31, 54, 60, 73, 97]. Thus, the S396 antibody is commonly used to study early tau hyperphosphorylation in a range of species and AD models [1, 29]. In contrast, the phosphorylation of residues serine202 and threonine205, detected by the AT8 antibody, occurs in the latter stages of tau pathology [32]. Although it is likely that the absence of mature NFTs in the stock sheep reflects the relatively young age of the sheep, the presence of pre-tangles is indicative of early-stage tau pathology in sheep as young as 5–8 years of age [74]. As the preliminary study of a 21-year-old sheep detected numerous AT8-positive mature NFTs, it is likely that older sheep display advanced stage tau pathology as observed in AD, and that the pre-tangle pathology observed in younger sheep may eventually progress to this advanced stage. The variation in spontaneous tau and Aβ pathology observed between the very aged sheep in the pilot study also reflects the significant variability of tau and Aβ pathology observed in aged humans, further pointing to the sheep as a relevant animal model.
Phosphorylation of the serine396 residue was also investigated. We found phosphorylated S396 immunoreactivity was present in some sheep 2 years of age and that phosphorylation increased with age. While the observation of this pathology at such an early age may be surprising, it is consistent with human data where it has been shown that abnormal tau changes occur in the brain as early as childhood or puberty [8, 9]. Recent evidence also suggests that neurons undergo a dying back pattern of degeneration, where tau pathology begins in the axonal compartment before progressing to the somatodendritic compartment [14, 51]. The differential patterns of immunostaining within the CA3 region of the hippocampus observed using different anti-Aβ1–42 and anti-tau antibodies in this study may indicate early hippocampal intraneuronal Aβ deposition, accompanied by early-stage axonal tau phosphorylation. The presence of mOC64 and S396 immunopositivity may also indicate that these changes occur in sheep as young as approximately 2 years of age. The pattern of S396 labelling within the CA3 region of the hippocampus is remarkably similar to labelling detected using the same antibody in the hippocampus of cows with idiopathic brainstem neuronal chromatolysis (IBNC) [48]. While the exact aetiological cause of IBNC is unknown, studies have indicated that it is a complex proteinopathy characterised by significant hyperphosphorylated tau with associated secondary accumulations of alpha-synuclein and ubiquitin, without associated NFT formation or amyloid deposition [48]. Interestingly, while cases of IBNC are predominantly reported in cows > 6 years old, the youngest recorded case was in a cow just 4 years old. Therefore, further research into tau phosphorylation and tauopathy in sheep and large ruminants would be beneficial to determine if these two pathologies are related.
The current study identified diffuse plaque-like tau-positive deposits that were not characteristic of AD-like tau pathology. We found no background staining in the tissue surrounding these focal regions. All control slides were also negative, and the pattern of staining with the AT8 antibody on both AD-positive and AD-negative human control tissue revealed staining only of the AD brain. Given that the regional and age-dependent distribution of these AT8-positive elements is consistent with a progressive pathogenesis, it is possible that the AT8 antibody in this instance was accurately labelling phosphorylated tau. However, equally, while the use of the AT8 antibody is renowned for achieving specific phospho-tau labelling with little or no background signal [7, 30], this pattern of atypical staining may have resulted from non-specific antibody staining, tissue treatment artefacts, or cross reactivity with another species of tau. Further investigations into possible sources of this atypical AT8 labelling in sheep are necessary.
Tau isoform expression
In humans, all six of the tau isoforms expressed in the brain become hyper-phosphorylated and involved in tau pathology. MAPT splicing and tau isoform expression, however, differs between species, affecting the subsequent formation of tau pathology [40, 84, 92]. This study confirmed the expression of the four distinct ovine tau isoforms described by Janke et al. [47], formed from the splicing of exons 3 and 10. This pattern of ovine tau expression is consistent with the phylogenetic expression of tau in other ruminants [43, 47]. While exon 8 has previously been identified in transcripts from the rhesus macaque and the cow [66] the ovine tau transcripts generated in this study confirmed that exons 4a, 6 and 8 are not transcribed in sheep (for comparisons of tau expression between species, see Fig. 10). Janke et al. [47] also described two additional isoforms in sheep, interpreted as the two 0N tau isoforms, consistent with the two shortest tau isoforms expressed in humans. However, we found no evidence for the expression of these isoforms, resulting from the alternative splicing of exon 2. The confirmation that sheep express the 3R and 4R tau isoforms that are expressed in humans is an important step in assessing of their suitability as an AD model, particularly given that mice naturally express only 4R tau [3]. Possessing both 3R and 4R endogenous tau isoforms confers considerable potential to the sheep as an AD model with a highly translatable value.
The variations in the tau N-terminal domains of different species have been cited as reasons why tau pathology differs between species [3]. The human N-terminal domain contains an eleven amino acid motif (residues 17–28) not present within the N-terminal domain of murine tau [40]. This additional peptide sequence is thought to affect the intramolecular interactions between the N- and C-terminals, and the microtubule-binding domains of tau, increasing the likelihood of normal tau undergoing pathological conformational changes [3, 40]. The lack of this N eleven amino acid motif in murine tau has been suggested as one reason why mice do not naturally develop tau pathology [40]. Additionally, within the first 190N-terminal amino acids, human tau contains 33 serine, threonine, and tyrosine residues. Murine tau shares 22 of these residues. Many of the residues, found in humans (but lacking in mice) are phosphorylated in AD, or are phosphorylated by kinases that exhibit dysregulation in AD [37]. However, an alignment of the human, murine and ovine tau proteins show that sheep lack the eleven amino acid sequence, and many of the same phosphorylation sites as murine tau, even though they naturally develop tau pathology [7, 64, 65, 74]. We speculate that while the presence of the 11 amino acid motif and the phosphorylation of these residues may accelerate pathological tau formation in humans, their involvement is not essential for the development of PHF tau.
Proline-rich regions facilitate the phosphorylation of serine and threonine residues via kinases thought to have key roles in the pathogenesis of AD [44]. There are seven distinct variations between the human and ovine proline-rich regions of tau that may be implicated in tau hyperphosphorylation in the sheep. For example, proline176, alanine178 and proline182 in human tau are substituted with threonine, threonine and serine, respectively, in ovine tau. However, proline residues that are important for the directed phosphorylation of tyrosine residues such as proline213, proline216 and proline219 are conserved between humans and sheep [40, 56]. Additionally, each of the four KXGS motifs which can be phosphorylated by multiple kinases, and the four PGGG sequences which facilitate the formation of type II β-turns and β-hairpin structures, are conserved between humans and sheep [13, 21].
Future work
As only three other studies have applied phosphorylation dependent antibodies to study the ovine brain, further work is required to elucidate the residue specific patterns of tau phosphorylation in sheep as they age. Although this study focused on the hippocampus and entorhinal cortex, critical regions for the development of AD pathology, future studies would benefit from analysing other cortical and subcortical structures that have been implicated in the early tau pathology of both humans and aged canines, such as the thalamus [1]. The investigation of other tau post-translational modifications, such as truncation would also be valuable as truncation has been associated with increased tau aggregation in AD [55]. A complete evaluation of other protein pathologies, markers of astrogliosis and neuroinflammation, such as those involving ubiquitin, APOE and GFAP would also be beneficial since this would provide a more complete picture of AD-related pathology in sheep [57]. Environmental factors that could increase the likelihood of sheep develo** AD-like pathologies also need to be investigated. For example, both copper (to which sheep are sensitive), and rumen-protected feed ingredients such as formaldehyde are factors that have been implicated in AD pathogenesis [48, 87, 99]. They may contribute to the AD-like pathology observed in other young ruminants. Future studies will also benefit from a complete evaluation of potential heterozygous substitutions and single nucleotide polymorphisms of the ovine MAPT transcript. Finally, screening sheep for relevant alleles, such as APOEε4 may help to enhance the detection of AD-like pathological characteristics in the commercial sheep population, increasing their potential suitability of being a natural AD model [74, 94].
Conclusion
We identified intracellular and vascular Aβ deposition in the brains of sheep as young as 2 years of age. We also identified AT8-positive pre-neurofibrillary tangles in sheep > 5 years of age. One of the early stages in the conversion of normal to pathological tau is the phosphorylation of multiple residues. We show that even by 2 years of age, some phosphorylation of the serine396 residue is present in sheep, and the relative amount of tau phosphorylated at this residue increases with advancing age. Given that these findings are consistent with early-stage AD-like pathology, sheep could be used to investigate the early biochemical and structural changes that eventually result in advanced AD-like pathology, without the complications of late-stage pathology. This would be an important step, given that the disease course of rodent transgenic AD models often progresses too rapidly for a comprehensive evaluation of this pre-clinical phase of AD aetiology to be completed [23]. Our pilot study detected numerous NFTs in a sheep 21 years of age, indicating that the development of late-stage tau pathology is possible in older sheep. This study has also confirmed that sheep express four distinct tau isoforms in their CNS, composed of three and four binding repeats, which result from the alternative splicing of exons 3 and 10. As a result, the sheep, either as a spontaneous model with genetic predisposition or, as a transgenic model, has the potential to provide a valuable model of early-stage AD-like tauopathy, reflective of that seen in humans.
Data availability
Supplementary information accompanies this paper. Datasets analysed and presented in the current study are available from the corresponding author on request.
Abbreviations
- AD:
-
Alzheimer’s disease
- Aβ:
-
β-Amyloid
- CAA:
-
Cerebral amyloid angiopathy
- NFTs:
-
Neurofibrillary tangles
- APP:
-
Amyloid precursor protein
- PSEN1:
-
Presenilin 1
- PSEN:
-
Presenilin 2
- FTDP-17:
-
Frontotemporal dementia with parkinsonism-17
- FAD:
-
Familial Alzhimer’s disease
- TBS:
-
Tris-buffered saline
- RT:
-
Room temperature
- DTT:
-
Dithiothreeitol
- TTBS:
-
Tween 20 tris buffered saline
- BCIP/NBT:
-
5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium
- IPTG:
-
Isopropyl β-d-1-thiogalactopyranoside
- X-GAL:
-
5-Bromo-4-chloro-3-indolyl β-d-galactopyranoside
- X-GAL:
-
Luria–Bertani
- IBNC:
-
Idiopathic brainstem neuronal chromatolysis
- CNS:
-
Central nervous system
- MAPT:
-
Microtubule associated protein tau
- PCR:
-
Polymerase chain reaction
- ANOVA:
-
Analysis of variance
- CA3:
-
Cornu ammonis 3
- NCBI:
-
National Centre for Biotechnology Information
- PHFs:
-
Paired helical filaments
- APOE:
-
Apolipoprotein
- GFAP:
-
Glial fibrillary acidic protein
References
Abey A, Davies D, Goldsbury C, Buckland M, Valenzuela M, Duncan T (2021) Distribution of tau hyperphosphorylation in canine dementia resembles early Alzheimer’s disease and other tauopathies. Brain Pathol 31(1):144–162
Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I (2010) Immunohistochemical visualization of amyloid-β protein precursor and amyloid-β in extra-and intracellular compartments in the human brain. J Alzheimers Dis 20(4):1015–1028
Ando K, Leroy K, Héraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP (2011) Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178(2):803–816
Arnsten AF, Datta D, Leslie S, Yang ST, Wang M, Nairn AC (2019) Alzheimer’s-like pathology in aging rhesus macaques: unique opportunity to study the etiology and treatment of Alzheimer’s disease. Proc Natl Acad Sci 116(52):26230–26238
Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer’s disease. Acta Neuropathol 103(1):26–35
Bond M, Kleine Holthaus SM, Tammen I, Tear G, Russell C (2013) Use of model organisms for the study of neuronal ceroid lipofuscinosis. Biochimica et Biophysica Acta (BBA) Mol Basis Dis 1832(11):1842–1865
Braak H, Braak E, Strothjohann M (1994) Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett 171(1–2):1–4
Braak H, Del Tredici K (2011) The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 121(2):171–181
Braak H, Del Tredici K (2012) Where, when, and in what form does sporadic Alzheimer’s disease begin? Curr Opin Neurol 25(6):708–714
Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Rev 33(1):95–130
Calderon-Garcidueñas AL, Duyckaerts C (2018) Alzheimer disease. Handbook of clinical neurology, vol 145. Elsevier, Amsterdam, pp 325–337
Chambers JK, Tokuda T, Uchida K, Ishii R, Tatebe H, Takahashi E, Tomiyama T, Une Y, Nakayama H (2015) The domestic cat as a natural animal model of Alzheimer’s disease. Acta Neuropathol Commun 3(1):78
Chen D, Drombosky KW, Hou Z, Sari L, Kashmer OM, Ryder BD, Perez VA, Woodard DR, Lin MM, Diamond MI, Joachimiak LA (2019) Tau local structure shields an amyloid-forming motif and controls aggregation propensity. Nat Commun 10(1):1–14
Christensen KR, Beach TG, Serrano GE, Kanaan NM (2019) Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways. Acta Neuropathol Commun 7(1):1–21
Cocquyt G, Driessen B, Simoens P (2005) Variability in the eruption of the permanent incisor teeth in sheep. Vet Rec 157(20):619–623
Cork LC, Powers RE, Selkoe DJ, Davies P, Geyer JJ, Price DL (1988) Neurofibrillary tangles and senile plaques in aged bears. J Neuropathol Exp Neurol 47(6):629–641
Cummings BJ, Su JH, Cotman CW, White R, Russell MJ (1993) β-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer’s disease. Neurobiol Aging 14(6):547–560
Cummings BJ, Head E, Afagh AJ, Milgram NW, Cotman CW (1996) β-Amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol Learn Mem 66(1):11–23
D’Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer’s disease. Histopathology 38:120–134
DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 14(1):1–18
Dehmelt L, Halpain S (2004) The MAP2/Tau family of microtubule-associated proteins. Genome Biol 6(1):204
Drummond E, Wisniewski T (2017) Alzheimer’s disease: experimental models and reality. Acta Neuropathol 133(2):155–175
Eaton SL, Wishart TM (2017) Bridging the gap: large animal models in neurodegenerative research. Mamm Genome 28(7–8):324–337
Eaton SL, Proudfoot C, Lillico SG, Skehel P, Kline RA, Hamer K, Rzechorzek NM, Clutton E, Gregson R, King T, O’Neill CA (2019) CRISPR/Cas9 mediated generation of an ovine model for infantile neuronal ceroid lipofuscinosis (CLN1 disease). Sci Rep 9(1):1–8
Edler MK, Sherwood CC, Meindl RS, Hopkins WD, Ely JJ, Erwin JM, Mufson EJ, Hof PR, Raghanti MA (2017) Aged chimpanzees exhibit pathologic hallmarks of Alzheimer’s disease. Neurobiol Aging 59:107–120
Elder GA, Gama Sosa MA, De Gasperi R (2010) Transgenic mouse models of Alzheimer’s disease. Mt Sinai J Med J Transl Personal Med 77(1):69–81
Ella A, Delgadillo JA, Chemineau P, Keller M (2017) Computation of a high-resolution MRI 3D stereotaxic atlas of the sheep brain. J Comp Neurol 525(3):676–692
Flattery CNR, Rosen RF, Farberg AS, Dooyema JM, Hof PR, Sherwood CC, Walker LC, Preuss TM (2020) Quantification of neurons in the hippocampal formation of chimpanzees: comparison to rhesus monkeys and humans. Brain Struct Funct 225(8):2521–2531
Foidl BM, Humpel C (2018) Differential hyperphosphorylation of tau-S199,-T231 and-S396 in organotypic brain slices of Alzheimer mice. A model to study early tau hyperphosphorylation using okadaic acid. Front Aging Neurosci 10:113
Gearing M, Rebeck GW, Hyman BT, Tigges J, Mirra SS (1994) Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. Proc Natl Acad Sci 91(20):9382–9386
Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P (1994) Epitope map** of monoclonal antibodies to the paired helical filaments of Alzheimer’s disease: identification of phosphorylation sites in tau protein. Biochem J 301(3):871–877
Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189(3):167–170
Gouras GK, Tsai J, Naslund J et al (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156:15–20
Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010) Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol 119(5):523–541
Geula C, Nagykery N, Wu CK (2002) Amyloid-β deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition. Acta Neuropathol 103(1):48–58
Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. In Nucleic acids symposium series 41:95–98
Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, Anderton BH (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282(32):23645–23654
Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12:383–388
Hatami A, Albay R, Monjazeb S, Milton S, Glabe C (2014) Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. J Biol Chem 289(46):32131–32143
Hernández F, Merchán-Rubira J, Vallés-Saiz L, Rodríguez-Matellán A, Avila J (2020) Differences between human and murine Tau at the N-terminal end. Front Aging Neurosci 12:11
Heuer E, Rosen FR, Cintron A, Walker CL (2012) Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr Pharm Design 18(8):1159–1169
Hohsfield LA, Humpel C (2015) Migration of blood cells to β-amyloid plaques in Alzheimer’s disease. Exp Gerontol 65:8–15
Himmler A (1989) Structure of the bovine tau gene: alternatively spliced transcripts generate a protein family. Mol Cell Biol 9(4):1389–1396
Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 104(6):1433–1439
Hough D, Bellingham M, Haraldsen IRH, McLaughlin M, Rennie M, Robinson JE, Solbakk AK, Evans NP (2017) Spatial memory is impaired by peripubertal GnRH agonist treatment and testosterone replacement in sheep. Psychoneuroendocrinology 75:173–182
Jacobsen JC, Bawden CS, Rudiger SR, McLaughlan CJ, Reid SJ, Waldvogel HJ, MacDonald ME, Gusella JF, Walker SK, Kelly JM, Webb GC (2010) An ovine transgenic Huntington’s disease model. Hum Mol Genet 19(10):1873–1882
Janke C, Beck M, Stahl T, Holzer M, Brauer K, Bigl V, Arendt T (1999) Phylogenetic diversity of the expression of the microtubule-associated protein tau: implications for neurodegenerative disorders. Mol Brain Res 68(1–2):119–128
Jeffrey M, Piccardo P, Ritchie DL, Ironside JW, Green AJ, McGovern G (2015) A naturally occurring bovine tauopathy is geographically widespread in the UK. PLoS ONE 10(6):e0129499
Jiang Y, **e M, Chen W, Talbot R et al (2014) The sheep genome illuminates biology of the rumen and lipid metabolism. Science 344:1168–1173
Kametani F, Hasegawa M (2018) Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer’s disease. Front Neurosci 12:25
Kanaan NM, Pigino GF, Brady ST, Lazarov O, Binder LI, Morfini GA (2013) Axonal degeneration in Alzheimer’s disease: when signaling abnormalities meet the axonal transport system. Exp Neurol 246:44–53
Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28:1297–1306
Kosenko E, Tikhonova L, Alilova G, Urios A, Montoliu C (2020) The erythrocytic hypothesis of brain energy crisis in sporadic Alzheimer disease: possible consequences and supporting evidence. J Clin Med 9(1):206
Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B (2016) Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer’s disease and track disease progression and cognitive decline. Acta Neuropathol 132(6):875–895
Kovacech B, Novak M (2010) Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer’s disease. Curr Alzheimer Res 7(8):708–716
Lau DH, Hogseth M, Phillips EC, O’Neill MJ, Pooler AM, Noble W, Hanger DP (2016) Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease. Acta Neuropathol Commun 4(1):1–13
Lowe J, Ince P, Revesz T. Neuropathology autopsy practice: post-mortem examination in dementia. The Royal College of Pathologists. Unique document number G116, 2014.
Maclean CJ, Baker HF, Ridley RM, Mori H (2000) Naturally occurring and experimentally induced β-amyloid deposits in the brains of marmosets (Callithrix jacchus). J Neural Transm 107(7):799–814
Mochizuki A, Tamaoka A, Shimohata A, Komatsuzaki Y, Shoji S (2000) Abeta42-positive non-pyramidal neurons around amyloid plaques in Alzheimer’s disease. Lancet 355:42–43
Mondragon-Rodriguez S, Perry G, Luna-Munoz J, Acevedo-Aquino MC, Williams S (2014) Phosphorylation of tau protein at sites Ser(396–404) is one of the earliest events in Alzheimer’s disease and Down syndrome. Neuropathol Appl Neurobiol 40:121–135
Morton AJ, Howland DS (2013) Large genetic animal models of Huntington’s disease. J Huntingt Dis 2(1):3–19
Morton AJ (2018) Large-brained animal models of Huntington’s disease: sheep. Huntington’s disease. Humana Press, New York, pp 221–239
Morton AJ, Middleton B, Rudiger S, Bawden CS, Kuchel TR, Skene DJ (2020) Increased plasma melatonin in presymptomatic Huntington disease sheep (Ovis aries): compensatory neuroprotection in a neurodegenerative disease? J Pineal Res 68(2):e12624
Nelson PT, Greenberg SG, Saper CB (1994) Neurofibrillary tangles in the cerebral cortex of sheep. Neurosci Lett 170(1):187–190
Nelson PT, Saper CB (1995) Ultrastructure of neurofibrillary tangles in the cerebral cortex of sheep. Neurobiol Aging 16(3):315–323
Nelson PT, Stefansson K, Gulcher J, Saper CB (1996) Molecular evolution of τ protein: implications for Alzheimer’s disease. J Neurochem 67(4):1622–1632
Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Rönicke R, Reymann K (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β. Nature 485(7400):651–655
Oakley H, Cole SL, Logan S et al (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26:10129–10140
Oddo S, Caccamo A, Shepherd JD et al (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421
Pensalfini A, Albay R III, Rasool S, Wu JW, Hatami A, Arai H, Margol L, Milton S, Poon WW, Corrada MM, Kawas CH (2014) Intracellular amyloid and the neuronal origin of Alzheimer neuritic plaques. Neurobiol Dis 71:53–61
Perez SE, Raghanti MA, Hof PR, Kramer L, Ikonomovic MD, Lacor PN, Erwin JM, Sherwood CC, Mufson EJ (2013) Alzheimer’s disease pathology in the neocortex and hippocampus of the western lowland gorilla (Gorilla gorilla gorilla). J Comp Neurol 521(18):4318–4338
Perez SE, Sherwood CC, Cranfield MR, Erwin JM, Mudakikwa A, Hof PR, Mufson EJ (2016) Early Alzheimer’s disease–type pathology in the frontal cortex of wild mountain gorillas (Gorilla beringei beringei). Neurobiol Aging 39:195–201
Regalado-Reyes M, Furcila D, Hernández F, Ávila J, DeFelipe J, León-Espinosa G (2019) Phospho-tau changes in the human CA1 during Alzheimer’s disease progression. J Alzheimers Dis 69(1):277–288
Reid SJ, Mckean NE, Henty K, Portelius E, Blennow K, Rudiger SR, Bawden CS, Handley RR, Verma PJ, Faull RL, Waldvogel HJ (2017) Alzheimer’s disease markers in the aged sheep (Ovis aries). Neurobiol Aging 58:112–119
Ricciarelli R, Fedele E (2017) The amyloid cascade hypothesis in Alzheimer’s disease: it’s time to change our mind. Curr Neuropharmacol 15(6):926–935
Robinson JE, Evans NP, Dumbell R, Solbakk A, Ropstad E, Haraldsen IRH (2014) Effects of inhibition of gonadotropin releasing hormone secretion on the response to novel objects in young male and female sheep. Psychoneuroendocrinology 40:130–139
Rodriguez-Callejas JD, Fuchs E, Perez-Cruz C (2016) Evidence of tau hyperphosphorylation and dystrophic microglia in the common marmoset. Front Aging Neurosci 8:315
Rosen RF, Farberg AS, Gearing M, Dooyema J, Long MP, Anderson DC, Davis-Turak J, Coppola G, Geschwind DH, Paré JF, Duong TQ (2008) Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol 509(3):259–270
Sani S, Traul D, Klink A, Niaraki N, Gonzalo-Ruiz A, Wu CK, Geula C (2003) Distribution, progression and chemical composition of cortical amyloid-β deposits in aged rhesus monkeys: similarities to the human. Acta Neuropathol 105(2):145–156
Sarasa M, Pesini P (2009) Natural non-transgenic animal models for research in Alzheimer’s disease. Curr Alzheimer Res 6(2):171–178
Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC (2017) APP mouse models for Alzheimer’s disease preclinical studies. EMBO J 36(17):2473–2487
Sawiak SJ, Perumal SR, Rudiger SR, Matthews L, Mitchell NL, McLaughlan CJ, Bawden CS, Palmer DN, Kuchel T, Morton AJ (2015) Rapid and progressive regional brain atrophy in CLN6 Batten disease affected sheep measured with longitudinal magnetic resonance imaging. PLoS ONE 10(7):e0132331
Scheffer S, Hermkens DM, van der Weerd L, de Vries HE, Daemen MJ (2021) Vascular hypothesis of Alzheimer disease: topical review of mouse models. Arterioscler Thromb Vasc Biol 41(4):1265–1283
Sharma G, Huo A, Kimura T, Shiozawa S, Kobayashi R, Sahara N, Ishibashi M, Ishigaki S, Saito T, Ando K, Murayama S (2019) Tau isoform expression and phosphorylation in marmoset brains. J Biol Chem 294(30):11433–11444
Skene DJ, Middleton B, Fraser CK, Pennings JL, Kuchel TR, Rudiger SR, Bawden CS, Morton AJ (2017) Metabolic profiling of presymptomatic Huntington’s disease sheep reveals novel biomarkers. Sci Rep 7(1):1–16
Smolek T, Madari A, Farbakova J, Kandrac O, Jadhav S, Cente M, Brezovakova V, Novak M, Zilka N (2016) Tau hyperphosphorylation in synaptosomes and neuroinflammation are associated with canine cognitive impairment. J Comp Neurol 524(4):874–895
Sparks DL, Schreurs BG (2003) Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer’s disease. Proc Natl Acad Sci 100(19):11065–11069
Stylianaki I, Komnenou AT, Posantzis D, Nikolaou K, Papaioannou N. (2019) Alzheimer’s disease-like pathological lesions in an aged bottlenose dolphin (Tursiops truncatus). Vet Rec Case Rep. 7(1):e000700
Sun HL, Chen SH, Yu ZY, Cheng Y, Tian DY, Fan DY, He CY, Wang J, Sun PY, Chen Y, Tan CR (2020) Blood cell-produced amyloid-β induces cerebral Alzheimer-type pathologies and behavioral deficits. Mol Psychiatry. 26 (10):5568–5577
Sündermann F, Fernandez MP, Morgan RO (2016) An evolutionary roadmap to the microtubule-associated protein MAP Tau. BMC Genomics 17(1):264
Tabira T, Chui DH, Kuroda S (2002) Significance of intracellular Abeta42 accumulation in Alzheimer’s disease. Front Biosci 7:a44–a49
Takaichi Y, Chambers JK, Takahashi K, Soeda Y, Koike R, Katsumata E, Kita C, Matsuda F, Haritani M, Takashima A, Nakayama H (2021) Amyloid β and tau pathology in brains of aged pinniped species (sea lion, seal, and walrus). Acta Neuropathol Commun 9(1):1–15
Tenreiro S, Eckermann K, Outeiro TF (2014) Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci 7:42
Tsunoda K, Yamamoto Y, Akiya Y, Sato K, Rajbhandary HB, Van Son H, Loc CB (1998) Apolipoprotein E polymorphism in sheep. Biochem Genet 36(11–12):395–405
Uchida K, Yoshino T, Yamaguchi R, Tateyama S, Kimoto Y, Nakayama H, Goto N (1995) Senile plaques and other senile changes in the brain of an aged American black bear. Vet Pathol 32(4):412–414
Uno H, Alsum PB, Dong S, Richardson R, Zimbric ML, Thieme CS, Houser WD (1996) Cerebral amyloid angiopathy and plaques, and visceral amyloidosis in aged macaques. Neurobiol Aging 17(2):275–281
Usenovic M, Niroomand S, Drolet RE, Yao L, Gaspar RC, Hatcher NG, Schachter J, Renger JJ, Parmentier-Batteur S (2015) Internalized tau oligomers cause neurodegeneration by inducing accumulation of pathogenic tau in human neurons derived from induced pluripotent stem cells. J Neurosci 35(42):14234–14250
Wirths O, Multhaup G, Bayer TA (2004) A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide—the first step of a fatal cascade. J Neurochem 91:513–520
Zhai R, Rizak J, Zheng NA, He X, Li Z, Yin Y, Su T, He Y, He R, Ma Y, Yang M (2018) Alzheimer’s disease-like pathologies and cognitive impairments induced by formaldehyde in non-human primates. Curr Alzheimer Res 15(14):1304–1321
Zhao L (2020) 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dement 16:391–460. https://doi.org/10.1002/alz.12068
Acknowledgements
The authors would like to acknowledge the technical assistance and support relating to brain sample collection provided by Naomi Gordon. We thank Kath Bretnall for the gift of the aged pilot sheep brains and Wendy Leavens and Zhiguang Zheng for histology and technical assistance relating to the pilot sheep data. We would also like to acknowledge the support received from the Translational Genomics Facility of Aberystwyth University, and we would like to thank the South West Dementia Brain Bank (SWDBB) for providing brain tissue for this study. The SWDBB is part of the Brains for Dementia Research programme, jointly funded by Alzheimer’s Research UK and Alzheimer’s Society. It is supported by BRACE (Bristol Research into Alzheimer's and Care of the Elderly) and the Medical Research Council.
Funding
This research was funded by NRN Life Sciences Research Network Wales.
Author information
Authors and Affiliations
Contributions
ED, AJM, RM and SMcB designed the study experiments, ED conducted the experiments, analysed the results, and wrote the manuscript. RM provided research equipment and technical expertise. DC provided technical expertise. SMcB, RM, DC and AJM critically revised the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
Authors have no competing interests.
Ethical approval
This study was conducted in accordance with the Scientific Procedures Act 1986 and the study received ethics approval and consent granted by Aberystwyth University’s Animal Welfare Ethical Review Body.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
18_2022_4572_MOESM2_ESM.tif
Supplementary file2 Fig. S1 Immunohistochemistry of brain cortex from a sheep 16 years of age (sheep #P2) using the anti-phospho tau antibody AT8. A; An example of an NFT where the cytoplasm and neurites remain defined. B; Examples of NFTs where the nucleus and cytoplasm are not distinguishable. Scale bars represent 50 μm (A) or 100 μm (B) (TIF 2847 KB)
18_2022_4572_MOESM3_ESM.tif
Supplementary file3 Fig. S2 Immunohistochemistry of AD positive (top row) and AD negative (bottom row) human control tissue. The anti-phospho tau antibody, AT8 (A & E), the anti-phospho tau antibody, S396 (B & F), the anti-Aβ1–42, ab12267 (C & G), and the anti-Aβ1–42 mOC64 antibody (D & H). Scale bars represent 200 µm (A-H). Fig. S3 Immunohistochemical control section from the entorhinal cortex of a sheep > 5 years of age. The primary antibody (anti-Aβ1–42 mOC64, as seen in Fig. 3; A) has been omitted. Scale bar represents 200 µm (TIF 20936 KB)
18_2022_4572_MOESM4_ESM.tif
Supplementary file4 Fig. S4: Schematic drawing of coronal sections of the sheep brain, representing the rostro-caudal distribution of AD-like pathologies in very old study pilot sheep (A; P1, B; P2), and stock sheep > 5 years of age (C). The left hemisphere viewed from the rostral aspect is illustrated. The approximate rostro-caudal positions of the coronal sections are illustrated in D. Solid triangles represent mature neurofibrillary tangles labelled with the anti-phospho-tau antibody AT8. Open triangles represent pre-neurofibrillary tangles and neuronal processes labelled with the anti-phospho-tau antibodies AT8 and S396. Solid circles represent diffuse plaques labelled with the anti-Aβ1–42 antibody ab12267. Open circles represent intra-neuronal labelling identified using the anti-Aβ1–42 antibody mOC64. The area enclosed by the box (B) represents the approximate location of Fig. 2; A. All gyri and sulci are labelled using the stereotaxis atlas of the ovine brain developed by Ella et al. [27]. C, caudate nucleus; CG, cingulate gyrus; EC, entorhinal cortex; F, fimbria; H, hippocampus; I, insular cortex; IC, internal capsule; LV, lateral ventricle; OC, olfactory cortex; OV, olfactory ventricle; P, putamen; RS, rhinal sulcus; SG, sylvian gyrus; SS, suprasylvian sulcus; SSG, suprasylvius gyrus (TIF 31288 KB)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Davies, E.S., Morphew, R.M., Cutress, D. et al. Characterization of microtubule-associated protein tau isoforms and Alzheimer’s disease-like pathology in normal sheep (Ovis aries): relevance to their potential as a model of Alzheimer’s disease. Cell. Mol. Life Sci. 79, 560 (2022). https://doi.org/10.1007/s00018-022-04572-z
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00018-022-04572-z